Institut Pasteur, Université Paris Cité, CNRS UMR2000, Unité Mycologie Moléculaire, Paris, France.
Laboratoire de Parasitologie-Mycologie, AP-HP, Hôpital Saint-Louis, Paris, France.
Nat Commun. 2024 Aug 14;15(1):6966. doi: 10.1038/s41467-024-51047-9.
Pentraxin 3 (PTX3), a long pentraxin and a humoral pattern recognition molecule (PRM), has been demonstrated to be protective against Aspergillus fumigatus, an airborne human fungal pathogen. We explored its mode of interaction with A. fumigatus, and the resulting implications in the host immune response. Here, we demonstrate that PTX3 interacts with A. fumigatus in a morphotype-dependent manner: (a) it recognizes germinating conidia through galactosaminogalactan, a surface exposed cell wall polysaccharide of A. fumigatus, (b) in dormant conidia, surface proteins serve as weak PTX3 ligands, and (c) surfactant protein D (SP-D) and the complement proteins C1q and C3b, the other humoral PRMs, enhance the interaction of PTX3 with dormant conidia. SP-D, C3b or C1q opsonized conidia stimulated human primary immune cells to release pro-inflammatory cytokines and chemokines. However, subsequent binding of PTX3 to SP-D, C1q or C3b opsonized conidia significantly decreased the production of pro-inflammatory cytokines/chemokines. PTX3 opsonized germinating conidia also significantly lowered the production of pro-inflammatory cytokines/chemokines while increasing IL-10 (an anti-inflammatory cytokine) released by immune cells when compared to the unopsonized counterpart. Overall, our study demonstrates that PTX3 recognizes A. fumigatus either directly or by interplaying with other humoral PRMs, thereby restraining detrimental inflammation. Moreover, PTX3 levels were significantly higher in the serum of patients with invasive pulmonary aspergillosis (IPA) and COVID-19-associated pulmonary aspergillosis (CAPA), supporting previous observations in IPA patients, and suggesting that it could be a potential panel-biomarker for these pathological conditions caused by A. fumigatus.
五聚素 3(PTX3)是一种长型五聚素和体液模式识别分子(PRM),已被证明可抵抗空气中的人类真菌病原体烟曲霉。我们探索了它与烟曲霉相互作用的方式,以及对宿主免疫反应的影响。在这里,我们证明 PTX3 以形态依赖的方式与烟曲霉相互作用:(a)它通过半乳糖胺半乳糖识别发芽的分生孢子,这是烟曲霉表面暴露的细胞壁多糖,(b)在休眠的分生孢子中,表面蛋白充当弱的 PTX3 配体,(c)表面活性剂蛋白 D(SP-D)和补体蛋白 C1q 和 C3b,其他体液 PRM,增强 PTX3 与休眠分生孢子的相互作用。SP-D、C3b 或 C1q 调理的分生孢子刺激人原代免疫细胞释放促炎细胞因子和趋化因子。然而,PTX3 随后与 SP-D、C1q 或 C3b 调理的分生孢子结合显著降低了促炎细胞因子/趋化因子的产生。与未调理的对照相比,PTX3 调理的发芽分生孢子也显著降低了促炎细胞因子/趋化因子的产生,同时增加了免疫细胞释放的抗炎细胞因子 IL-10。总的来说,我们的研究表明,PTX3 直接或通过与其他体液 PRM 相互作用来识别烟曲霉,从而抑制有害炎症。此外,侵袭性肺曲霉病(IPA)和 COVID-19 相关肺曲霉病(CAPA)患者血清中的 PTX3 水平明显升高,支持之前 IPA 患者的观察结果,并表明它可能是这些由烟曲霉引起的病理状况的潜在面板生物标志物。